findmyKOL
Clinical trialNCT02539459TerminatedPhase 2Interventional

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus

SponsorFox Chase Cancer CenterEnrollment20Sporadic Angiomyolipomas (AMLs)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney. They are composed of blood vessels, muscle cells and fat cells.Everolimus is already an approved drug for several other diseases like kidney cancer, but is being studied now specifically to see if it is helpful for people with AML.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Yale School of Medicine

    New Haven, Connecticut, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

  • Mayo Clinic

    Rochester, Minnesota, United States

  • Memorial Sloan Kettering

    New York, New York, United States

  • Duke University Health System

    Durham, North Carolina, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, United States

  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Everolimus →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
23 Sept 2015
Primary completion
20 Aug 2018
Completion
20 Aug 2018
Last update posted
15 Dec 2022
Registered enrollment
20
Registry id
NCT02539459
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.